scholarly journals Aptamer-polymer functionalized silicon nanosubstrates for enhanced recovered circulating tumor cell viability and in vitro chemosensitivity testing

2016 ◽  
pp. 2133 ◽  
Author(s):  
Qinglin Shen ◽  
Caixia Peng ◽  
Yan Zhan ◽  
Liang Fan ◽  
Mengyi Wang ◽  
...  
Keyword(s):  
Tumor Cell ◽  
Cell Viability ◽  
Circulating Tumor Cell ◽  
Chemosensitivity Testing ◽  
In Vitro Chemosensitivity

The MTS vs. the ATP assay for in vitro chemosensitivity testing of primary glioma tumour culture

2010 ◽  
Vol 36 (6) ◽  
pp. 564-567 ◽  
Author(s):  
T. P. Dawson ◽  
R. V. Iyer ◽  
R. W. Lea ◽  
P. Roberts ◽  
F. Harris ◽  
...  
Keyword(s):  
Chemosensitivity Testing ◽  
Atp Assay ◽  
In Vitro Chemosensitivity ◽  
Primary Glioma

scholarly journals Construction and Clinical Verification of Cytoplasm Protein GFAP as Circulating Tumor Cell Separation target for Pediatric Neuroepithelial Tumors

2020 ◽  
Author(s):  
Yang Zhao ◽  
Feng Jiang ◽  
Qinhua Wang ◽  
Baocheng Wang ◽  
Yipeng Han ◽  
...  
Keyword(s):  
Tumor Cell ◽  
Detection System ◽  
Invasive Procedure ◽  
Circulating Tumor Cell ◽  
Immunofluorescence Assay ◽  
Good Choice ◽  
Neuroepithelial Tumors ◽  
Prediction Function

Abstract BACKGROUND: Pediatric Neuroepithelial Tumors (NT) are one of the most prevalent diseases among children. Developing a highly efficient cerebrospinal fluid (CSF) detection system with diagnosis and prediction function is very important. Circulating tumor cell (CTC) in CSF is a good choice. In contrast to the past use of epithelial EpCAM as CTC separation target, an cytoplasm protein of GFAP antibody was first selected to construct highly-sensitive immunomagnetic liposomes (IMLs). The validation and efficiency of this system in capturing CTCs for NT were measured both in vitro and in vivo. The associations between the numbers of CTCs in patients with their clinical characteristics were further analyzed. RESULTS: Our data show that CTCs can be successfully isolated from CSF and blood samples from 29 children with NT. The numbers of CTCs in CSF were significantly higher than those in blood. The level of CTCs in CSF was related to the type and location of the tumor rather than its stage. Genetic testing in GFAP CTC-DNA by sanger sequencing, q-PCR and NGS methods indicated that the isolated CTCs (GFAP+/EGFR+) are the related tumor cell. For example, the high expression of NPR3 gene in CSF CTC was consistant with tumor tissue. CONCLUSIONS: GFAP-IML isolation of CTCs, combined with an EGFR immunofluorescence assay of antitumor marker, can serve as a brand-new method for the identification of CTCs for brain tumors. Via lumbar puncture, a minimally invasive procedure, this technique can be clinically significant in diagnosis and efficacy assessments of pediatric NT.

In vitro chemosensitivity testing of leukemic cells: Development of a semiautomated colorimetric assay

1989 ◽  
Vol 7 (3) ◽  
pp. 243-253 ◽  
Author(s):  
Pietro Antonio Bernabei ◽  
Valeria Santini ◽  
Luigi Silvestro ◽  
Orietta Dal Pozzo ◽  
Roberto Bezzini ◽  
...  
Keyword(s):  
Colorimetric Assay ◽  
Leukemic Cells ◽  
Chemosensitivity Testing ◽  
In Vitro Chemosensitivity

In Vitro Effect of Focused Ultrasound or Thermal Stress on HSP70 Expression and Cell Viability in Three Tumor Cell Lines

2007 ◽  
Vol 14 (7) ◽  
pp. 859-870 ◽  
Author(s):  
Walter Hundt ◽  
Caitlin E. O’Connell-Rodwell ◽  
Mark D. Bednarski ◽  
Silke Steinbach ◽  
Samira Guccione
Keyword(s):  
Thermal Stress ◽  
Tumor Cell ◽  
Cell Viability ◽  
Cell Lines ◽  
Focused Ultrasound ◽  
Hsp70 Expression ◽  
Tumor Cell Lines ◽  
Vitro Effect

Comparative Analysis of in Vitro Chemosensitivity to Four Proteasome Inhibitors in Human Myeloma Cell Lines

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 3436-3436
Author(s):  
Amit Kumar Mitra ◽  
Taylor S Harding ◽  
Brian Van Ness
Keyword(s):  
Multiple Myeloma ◽  
Cell Viability ◽  
Cell Lines ◽  
Proteasome Inhibitors ◽  
Genetic Characteristics ◽  
Myeloma Cells ◽  
In Vitro Chemosensitivity ◽  
Wide Range ◽  
Ic50 Values

Abstract Proteasome inhibitors (PI) are effective chemotherapeutic agents in the treatment of multiple myeloma (MM), used alone or in combination with other anti-cancer agents, such as alkylating agents, topoisomerase inhibitors, corticosteroids, histone deacetylase inhibitors (HDACis) and immunomodulatory drugs (IMiDs). Bortezomib (Velcade/Bz) was the first PI to be approved by US-FDA for the treatment of relapsed and refractory MM. Other second generation PIs include carfilzomib (Kyprolis/Cz), ixazomib/Iz and oprozomib (Opz). Wide inter-individual variation in response to treatment with PIs is a major limitation in achieving consistent therapeutic effect in MM. Yet few studies have compared the efficacy of all four PIs in a range of myeloma subtypes. In our current study, we performed comprehensive in vitro chemosensitivity profiling of response to four (4) PIs (Bz, Cz, Ix and Opz) in a panel of forty-five (45) human myeloma cells lines (HMCLs) generated through the immortalization of primary multiple myeloma cells (MMCs) and representing the biological and genetic heterogeneity of MM with regards to chromosomal abnormalities, oncogene mutations (e.g. Ras), tumor suppressor variations (e.g. p53), cell surface phenotypes, or growth factor response. Cells were treated with increasing concentrations of Bz, Cz, Ix and Opz as single agents and cell viability assays were performed using CellTiter-Glo luminescent cell viability assay to generate survival curves and determine the half maximal inhibitory concentration (IC50) values by calculating the nonlinear regression using sigmoidal dose-response equation (variable slope). Our results in comparing the cellular responses to PI treatment among HMCLs showed wide range of variability in IC50 values identifying some lines which were highly sensitive and some lines relatively refractory to PI treatment. Pearson product-moment correlation (PPMC) test demonstrated statistically significant (adjusted p values < 0.001) positive correlation between IC50 values of the following drug pairs: Bz vs Opz (r = 0.82); and Ix vs Opz (r = 0.88); Bz vs Ix (r = 0.65); Cz vs Opz (r = 0.69) and Cz vs Ix (r = 0.63). Subgroup analysis revealed significant correlation between carfizomib IC50 and chromosome number (p < 0.05). Furthermore, it was interesting to note that although all 4 drugs belong to the same drug class (PI), not all cell lines responded the same across all PI treatments. This demonstrates tumor heterogeneity even in response to inhibitors of the same class, and further demonstrates tumors refractory to one PI may still respond to another. We are currently examining genetic characteristics that are associated with response among the four PIs, and analysis of these characteristics will be presented. Disclosures No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document